Pyramid Analytics expands AI-driven Decision Intelligence with new OpenAI integration
20.3.2023 15:07:00 EET | Business Wire | Press release
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, announced today at the Gartner Data & Analytics Summit in Orlando, Florida, that the Pyramid 2023 release extends its already category-leading, AI-driven augmented capabilities with the integration of GPT (generative pre-trained transformer) AI technology from OpenAI—the company behind ChatGPT and DALL-E 2—throughout the platform, interoperating with its deep set of current AI technologies.
The release harnesses the new GPT AI engines to drive complex logic, data science, and machine learning code generation; AI-driven storytelling capabilities; and even AI-assisted design templates and colors. The effort extends Pyramid’s broader vision to enable and drive adoption across the enterprise by empowering all users to solve data-centric business problems through no-code and AI-assisted analytics and decision intelligence.
Key facts about Pyramid’s OpenAI integration
OpenAI is integrated throughout the Decision Intelligence Platform—including the data preparation, data science, the business analytics and spreadsheet modules, and the storyboard and publication designer modules.
- In data preparation: OpenAI can be used to generate SQL, DAX, and MDX code automatically for complex data extraction queries.
- In data science: OpenAI can be used to generate Python and R code automatically to drive machine learning logic.
- In spreadsheets: OpenAI can be used to build spreadsheet formulas for users constructing business models.
- In storyboarding and publications: OpenAI can be used to generate designs for content and graphics.
Separately, OpenAI can be used with existing natural language querying (NLQ) engines to drive and enhance broader insights on enterprise-specific data, ultimately improving the existing tools for delivering automated storytelling and textual analysis.
Market recognition
Pyramid has long been recognized as an innovator in the decision intelligence and analytics space. The company’s Decision Intelligence Platform was ranked #1 —by leading analyst firm Gartner—for “Augmented Analytics” in the 2022 Gartner Analytics and Business Intelligence (ABI) Critical Capabilities report.
Other leading analysts—such as 451 Research , Ventana Research , Dresner Advisory Services , and BARC —recognize Pyramid for its platform-based approach to no-code capabilities and AI/augmented analytics to enable all user types to drive sophisticated analytics easily. Critically, Pyramid’s existing augmented capabilities (NLQ, Chatbot, Smart Insights, Smart Model, Auto Discovery, Fill in the Blanks, Explain, etc.) uniquely operate directly on enterprise data without data duplication, custom models, proprietary data layers, or specialized data treatments.
Demos
Click here to schedule a demo of the Pyramid Decision Intelligence Platform and to learn more about OpenAI on the platform.
Quotes
Avi Perez, CTO and Co-Founder, Pyramid Analytics : “By integrating OpenAI throughout the Pyramid Decision Intelligence Platform, we are extending our existing AI and augmented capabilities with the latest generative AI tech, transforming—and simplifying—the decision-making experience further. As a no-code/low-code platform, Pyramid is designed to extend advanced analytics—from descriptive to predictive to prescriptive—for non-technical businesspeople, allowing them to make informed decisions that drive business outcomes.”
Omri Kohl, CEO and Co-Founder, Pyramid Analytics: “At Pyramid, we believe the key to widespread adoption of data analytics requires an analytics experience that meets different people’s needs, regardless of their technical skills or analytics aptitude. By strategically integrating generative AI technologies like OpenAI, we are taking our AI vision to the next level.”
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005287/en/
Contact information
Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom